229 related articles for article (PubMed ID: 28114285)
21. Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia.
Benkisser-Petersen M; Buchner M; Dörffel A; Dühren-von-Minden M; Claus R; Kläsener K; Leberecht K; Burger M; Dierks C; Jumaa H; Malavasi F; Reth M; Veelken H; Duyster J; Zirlik K
PLoS One; 2016; 11(12):e0169159. PubMed ID: 28036404
[TBL] [Abstract][Full Text] [Related]
22. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
23. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
Balakrishnan K; Peluso M; Fu M; Rosin NY; Burger JA; Wierda WG; Keating MJ; Faia K; O'Brien S; Kutok JL; Gandhi V
Leukemia; 2015 Sep; 29(9):1811-22. PubMed ID: 25917267
[TBL] [Abstract][Full Text] [Related]
24. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
Hill RJ; Lou Y; Tan SL
Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic acidic nuclear phosphoproteins ANP32C/D are novel clients of heat shock protein 90.
Yuzefovych Y; Blasczyk R; Huyton T
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2338-48. PubMed ID: 26112988
[TBL] [Abstract][Full Text] [Related]
26. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
Usmani SZ; Bona RD; Chiosis G; Li Z
J Hematol Oncol; 2010 Oct; 3():40. PubMed ID: 20977755
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
[TBL] [Abstract][Full Text] [Related]
28. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
Lin K; Rockliffe N; Johnson GG; Sherrington PD; Pettitt AR
Oncogene; 2008 Apr; 27(17):2445-55. PubMed ID: 17982489
[TBL] [Abstract][Full Text] [Related]
29. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
[TBL] [Abstract][Full Text] [Related]
30. The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia.
Grzywnowicz M; Karabon L; Karczmarczyk A; Zajac M; Skorka K; Zaleska J; Wlasiuk P; Chocholska S; Tomczak W; Bojarska-Junak A; Dmoszynska A; Frydecka I; Giannopoulos K
Leuk Lymphoma; 2015; 56(10):2908-13. PubMed ID: 25682964
[TBL] [Abstract][Full Text] [Related]
31. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.
Li HK; Matsumoto Y; Furusawa Y; Kamada T
J Radiat Res; 2016 Sep; 57(5):572-575. PubMed ID: 27242340
[TBL] [Abstract][Full Text] [Related]
32. AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.
Cosimo E; Tarafdar A; Moles MW; Holroyd AK; Malik N; Catherwood MA; Hay J; Dunn KM; Macdonald AM; Guichard SM; O'Rourke D; Leach MT; Sansom OJ; Cosulich SC; McCaig AM; Michie AM
Clin Cancer Res; 2019 Mar; 25(5):1574-1587. PubMed ID: 30559170
[TBL] [Abstract][Full Text] [Related]
33. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.
Segawa T; Fujii Y; Tanaka A; Bando S; Okayasu R; Ohnishi K; Kubota N
Int J Mol Med; 2014 Mar; 33(3):559-64. PubMed ID: 24366006
[TBL] [Abstract][Full Text] [Related]
34. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.
Moulick K; Ahn JH; Zong H; Rodina A; Cerchietti L; Gomes DaGama EM; Caldas-Lopes E; Beebe K; Perna F; Hatzi K; Vu LP; Zhao X; Zatorska D; Taldone T; Smith-Jones P; Alpaugh M; Gross SS; Pillarsetty N; Ku T; Lewis JS; Larson SM; Levine R; Erdjument-Bromage H; Guzman ML; Nimer SD; Melnick A; Neckers L; Chiosis G
Nat Chem Biol; 2011 Sep; 7(11):818-26. PubMed ID: 21946277
[TBL] [Abstract][Full Text] [Related]
35. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
Caldas-Lopes E; Cerchietti L; Ahn JH; Clement CC; Robles AI; Rodina A; Moulick K; Taldone T; Gozman A; Guo Y; Wu N; de Stanchina E; White J; Gross SS; Ma Y; Varticovski L; Melnick A; Chiosis G
Proc Natl Acad Sci U S A; 2009 May; 106(20):8368-73. PubMed ID: 19416831
[TBL] [Abstract][Full Text] [Related]
36. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells.
Efremov DG; Gobessi S; Longo PG
Autoimmun Rev; 2007 Dec; 7(2):102-8. PubMed ID: 18035318
[TBL] [Abstract][Full Text] [Related]
37. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
[TBL] [Abstract][Full Text] [Related]
38. Expression levels of Lyn, Syk, PLCγ2 and ERK in patients with chronic lymphocytic leukemia, and higher levels of Lyn are associated with a shorter treatment-free survival.
Wang YH; Fan L; Wang L; Zhang R; Zou ZJ; Fang C; Zhang LN; Li JY; Xu W
Leuk Lymphoma; 2013 Jun; 54(6):1165-70. PubMed ID: 23039362
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
40. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]